JP7824934B2 - 操作されたナチュラルキラー細胞の増殖および細胞毒性の増強およびその使用 - Google Patents

操作されたナチュラルキラー細胞の増殖および細胞毒性の増強およびその使用

Info

Publication number
JP7824934B2
JP7824934B2 JP2023514397A JP2023514397A JP7824934B2 JP 7824934 B2 JP7824934 B2 JP 7824934B2 JP 2023514397 A JP2023514397 A JP 2023514397A JP 2023514397 A JP2023514397 A JP 2023514397A JP 7824934 B2 JP7824934 B2 JP 7824934B2
Authority
JP
Japan
Prior art keywords
cells
population
culture
engineered
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023514397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539361A5 (cg-RX-API-DMAC7.html
JP2023539361A (ja
Inventor
バーナビー トレイガー,ジェイムズ
ライダ リアナ ラゼティック,アレクサンドラ
ジャンボレツ,キャサリン
ナフィースル ラフマン,ムハンマド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nkarta Inc
Original Assignee
Nkarta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nkarta Inc filed Critical Nkarta Inc
Publication of JP2023539361A publication Critical patent/JP2023539361A/ja
Publication of JP2023539361A5 publication Critical patent/JP2023539361A5/ja
Application granted granted Critical
Publication of JP7824934B2 publication Critical patent/JP7824934B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2023514397A 2020-09-02 2021-08-31 操作されたナチュラルキラー細胞の増殖および細胞毒性の増強およびその使用 Active JP7824934B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073671P 2020-09-02 2020-09-02
US63/073,671 2020-09-02
PCT/US2021/071330 WO2022051749A1 (en) 2020-09-02 2021-08-31 Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereof

Publications (3)

Publication Number Publication Date
JP2023539361A JP2023539361A (ja) 2023-09-13
JP2023539361A5 JP2023539361A5 (cg-RX-API-DMAC7.html) 2024-09-10
JP7824934B2 true JP7824934B2 (ja) 2026-03-05

Family

ID=80492150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514397A Active JP7824934B2 (ja) 2020-09-02 2021-08-31 操作されたナチュラルキラー細胞の増殖および細胞毒性の増強およびその使用

Country Status (9)

Country Link
US (1) US20230265390A1 (cg-RX-API-DMAC7.html)
EP (1) EP4204560A4 (cg-RX-API-DMAC7.html)
JP (1) JP7824934B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230058167A (cg-RX-API-DMAC7.html)
CN (1) CN116568805A (cg-RX-API-DMAC7.html)
AU (1) AU2021337000A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191047A1 (cg-RX-API-DMAC7.html)
IL (1) IL300903A (cg-RX-API-DMAC7.html)
WO (1) WO2022051749A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
WO2024163619A1 (en) * 2023-02-01 2024-08-08 Nkarta, Inc. Methods for expanding immune cells and related compositions and uses thereof
KR102669705B1 (ko) * 2023-02-24 2024-06-10 이엔셀 주식회사 제대혈 유래 자연 살해 세포의 확장배양방법
KR20240175366A (ko) * 2023-06-12 2024-12-20 한국화학연구원 Nk 세포의 증식 촉진 또는 활성화용 조성물 및 그의 용도
WO2025220989A1 (ko) * 2024-04-16 2025-10-23 주식회사 유씨아이테라퓨틱스 자연살해세포의 증폭 및 형질 도입 효율 증진용 피더 세포

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3487991B1 (en) * 2016-07-25 2022-09-07 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing modified natural killer cells and methods of use
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
AU2018227583B2 (en) * 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
MX2019011570A (es) * 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
WO2019165121A1 (en) * 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
CN113226340A (zh) * 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
AU2020321354A1 (en) * 2019-07-31 2022-03-03 Nkarta, Inc. Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Acta Pharmacologica Sinica,2018年,Vol.39,pp.167-176,doi: 10.1038/aps.2017.125
Cytotherapy,2012年,Vol.14, No.9,pp.1131-1143 (pp.1-24),doi:10.3109/14653249.2012.700767
Cytotherapy,2020年03月23日,Vol.22, No.7,pp.354-368,https://doi.org/10.1016/j.jcyt.2020.02.004
Frontiers in Immunology,2017年,Vol.8, Article 458,pp.1-18,doi: 10.3389/fimmu.2017.00458
Int. J. Mol. Sci.,2019年,Vol.20 ,443,doi:10.3390/ijms20020443
INTERNATIONAL JOURNAL OF ONCOLOGY,2015年,Vol.47,pp.335-342,DOI: 10.3892/ijo.2015.3005
Stimulatory cells plus IL-12 and IL-18 augments NK cell expansion, transduction, memory phenotype, and in vitro and in vivo CAR NK cytotoxicity & persistence,nkarta, PUBLICATIONS, PRESENTATIONS & POSTERS,2019年11月,SITC ,p.1,<インターネット>https://www.nkartatx.com/publications/ [検索日:2025/07/17]

Also Published As

Publication number Publication date
IL300903A (en) 2023-04-01
KR20230058167A (ko) 2023-05-02
EP4204560A4 (en) 2024-10-16
CA3191047A1 (en) 2022-03-10
CN116568805A (zh) 2023-08-08
WO2022051749A1 (en) 2022-03-10
AU2021337000A9 (en) 2023-07-13
EP4204560A1 (en) 2023-07-05
AU2021337000A1 (en) 2023-05-11
JP2023539361A (ja) 2023-09-13
US20230265390A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
JP7724765B2 (ja) ナチュラルキラー細胞の増殖を亢進する、および細胞障害性を増強するための方法および組成物
JP2023539361A (ja) 操作されたナチュラルキラー細胞の増殖および細胞毒性の増強およびその使用
JP7451468B2 (ja) 非造血組織常在性γδ T細胞の増幅および該細胞の使用
JP6788629B2 (ja) 濃縮された腫瘍反応性t細胞集団を腫瘍から作製する方法
EP3307875B1 (en) Methods for the production of tcr gamma delta+ t cells
CN110494558B (zh) Gamma delta t细胞和增强其杀肿瘤活性的方法
US20200223918A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
JP7817937B2 (ja) 腫瘍反応性t細胞のエクスビボ富化および増大のための方法ならびに関連するその組成物
US20180162939A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
TW202538050A (zh) 製備表現嵌合抗原受體的細胞之方法
JP2025156345A (ja) 免疫療法のためのnk細胞組成物および調製物ならびにそれらの製造のための方法
TW202241508A (zh) 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
KR20180133480A (ko) 표적화 핵산 나노수송체를 이용하여 치료 세포를 프로그램화하기 위한 조성물 및 방법
JP2020516238A (ja) ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株
TW201713768A (zh) 嵌合抗原受體(car)、組合物及其使用方法
JP2024501020A (ja) 操作されたガンマデルタt細胞ならびにその作製方法および使用方法
JP2019170176A (ja) ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用
WO2023206938A1 (zh) 一种靶向ccr8的嵌合抗原受体t细胞及其制备方法和应用
KR20220004028A (ko) 동종 car t 세포를 제조하는 방법
JP7748944B2 (ja) Nk細胞と抗体との結合を安定化する方法、及びその利用
RU2839702C2 (ru) Способы и композиции для усиления размножения и цитотоксичности клеток, являющихся натуральными киллерами
WO2025022372A1 (ja) 細胞集団の製造方法
Uetz-von et al. CAL-1 as Cellular Model System to Study CCR7-Guided Human Dendritic Cell Migration
WO2025095114A1 (ja) 改善された白血球の製造方法
Freud Studies of human natural killer cell development

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240830

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260220

R150 Certificate of patent or registration of utility model

Ref document number: 7824934

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150